<p>PDF file - 1679K, S Figure 1. Anti-miR-182 treatment for cell proliferation and invasion in normal and malignant ovarian cell lines in vitro. S Figure 2. Photomicrographs illustrating the surgical procedures of Orthotopic mouse model of ovarian cancer. S Figure 3. The general information of mice with anti-miR-182 treatment. S Figure 4. LIN28B, MYCN, and CA125 expression in mice with and without anti-miR-182 treatment. S Figure 5. Metastatic carcinomas in spleen and omentum. S Figure 6. Some miR-182 predicted target gene expression in mice with and without anti-miR-182 treatment. S Table 1. Primers and sequences used in this study. S Table 2. Antibody information used in this study. S Table 3. Metastasis analysis in mice with and without anti-miR-182 treatment.</p>
ARTICLE ABSTRACT
High-grade serous ovarian carcinoma (HGSOC) is a fatal disease, and its grave outcome is largely because of widespread metastasis at the time of diagnosis. Current chemotherapies reduce tumor burden, but they do not provide long-term benefits for patients with cancer. The aggressive tumor growth and metastatic behavior characteristic of these tumors demand novel treatment options such as anti-microRNA treatment, which is emerging as a potential modality for cancer therapy. MicroRNA-182 (miR182) overexpression contributes to aggressive ovarian cancer, largely by its negative regulation of multiple tumor suppressor genes involved in tumor growth, invasion, metastasis, and DNA instability. In this study, we examined the therapeutic potential of anti-miR182 utilizing the animal orthotopic model to mimic human ovarian cancer using ovarian cancer cells SKOV3 (intrabursal xenografts) and OVCAR3 (intraperitoneal injection). These models provide a valuable model system for the investigation of ovarian cancer therapy in vivo. Through a combination of imaging, histological, and molecular analyses, we found that anti-miR182 treatment can significantly reduce tumor burden (size), local invasion, and distant metastasis compared with its control in both models. The bases of anti-miR182 treatment are mainly through the restoration of miR182 target expression, including but not limited to BRCA1, FOXO3a, HMGA2, and MTSS1. Overall, our results strongly suggest that anti-miR182 can potentially be used as a therapeutic modality in treating HGSOC. Mol Cancer Ther; 13(7); 1729–39. ©2014 AACR.
